This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Humanitarian Device Exemption (HDE) Treatment Protocol For Treatment of Unresectable Hepatocellular Carcinoma

This study is currently recruiting participants.
See Contacts and Locations
Verified May 2017 by M.D. Anderson Cancer Center
BTG International Inc.
Information provided by (Responsible Party):
M.D. Anderson Cancer Center Identifier:
First received: August 4, 2010
Last updated: May 30, 2017
Last verified: May 2017

The goal of this study is to learn more about the patient experience, including any reported side effects and possible benefit related to the use of the TheraSphere device for treatment of liver cancer. Because treatment using the TheraSphere device must be designed specifically for each patient, the treatment process will also be monitored.

The Humanitarian Use Device Program is for FDA approved device that is safe and provides probable benefit.

Condition Intervention
Carcinoma, Hepatocellular Liver Cancer Device: TheraSphere Treatment

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Protocol For Use of TheraSphere® For Treatment of Unresectable Hepatocellular Carcinoma

Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • Overall Survival Associated With TheraSphere Treatment [ Time Frame: 3-6 weeks post treatment ]

Estimated Enrollment: 200
Actual Study Start Date: August 2010
Estimated Study Completion Date: August 2019
Estimated Primary Completion Date: August 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
TheraSphere Treatment
Injection via arterial catheter of TheraSphere microspheres containing yttrium-90 (Y-90) to whole liver, lobar or segmental treatment delivered as a sequence of treatments using approximately 30 - 90 days apart.
Device: TheraSphere Treatment
Injection via arterial catheter of TheraSphere microspheres containing yttrium-90 (Y-90) to whole liver, lobar or segmental treatment delivered as a sequence of treatments using approximately 30 - 90 days apart.

Detailed Description:

TheraSphere is a medical device containing yttrium-90 (Y-90), a radioactive material that has been used to treat liver tumors. When Y-90 is put into microscopic glass beads, called microspheres, it can be injected directly into the liver by artery. This allows a large dose of radiation to be delivered directly to the tumor, which lowers the risk of experiencing toxic radiation side effects from the radiation to in other parts of the body, or to healthy liver tissue. The radiation from TheraSphere treatment stays in the body and begins to lose its effect within 12 days, due to physical decay (please refer to the package insert for more information for more information regarding this). The glass microspheres will stay in the body from that point on, but should not cause any health problems.

All visits and procedures related to the TheraSphere treatment will be performed on an outpatient basis. About 2 weeks before the treatment begins, a small tube (catheter) will be inserted into an artery that goes to the liver, usually in the thigh.

TheraSphere Treatment:

TheraSphere (microspheres filled with Y-90 as described above) will be injected into the tumor in the liver through a catheter that you have already had placed into an artery during an earlier procedure.

You will receive at least 1 TheraSphere injection while you are receiving the treatment. If the doctor thinks it is needed, you will have a second injection about 1 month later. The number of TheraSphere injections you will receive will depend on the size and location of the tumors. The injection should take about 5 minutes to complete each time.

After receiving the TheraSphere injection, you will stay at the hospital for several hours so that the staff can check you for possible side effects. If you experience any serious problems or complications after receiving the injection, you may be admitted to the hospital for observation and possible additional treatment.

Length of Treatment:

You will continue to receive the HUD treatment indefinitely.

TheraSphere is a humanitarian use device that is approved by the FDA for the treatment of rare disorders affecting less than 4,000 people in the U.S. each year.

Up to 200 patients will receive the treatment. All will be enrolled at M.D. Anderson.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Diagnosis of unresectable intrahepatic HCC. The histopathology confirmation criterion may be waived in patients with a radiographically identifiable liver mass, known laboratory or clinical risk factors for cancer or elevated tumor markers such as alphafetoprotein (AFP)^21 and clinical findings. Guidelines from the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) describe in detail the approach and algorithm for diagnosing HCC.
  2. Eastern Cooperative Oncology Group (ECOG) Performance Status Score 0 - 1
  3. Life expectancy >/= 3 months
  4. > 4 weeks since prior radiation, surgery or chemotherapy
  5. Able to comprehend and provide written informed consent in accordance with institutional and federal guidelines.

Exclusion Criteria:

  1. Any pre-treatment laboratory findings within 15 days of treatment demonstrating liver dysfunction: • AST (Serum Glutamic-Oxalacetic Transaminase - SGOT) or ALT (Serum Glutamic-Pyruvic Transaminase - SGPT) > 5 times Upper Normal Limit (UNL) • Serum bilirubin > 2.0 mg/dl (unless segmental infusion is planned)
  2. Any contraindications to angiography and hepatic artery catheterization such as: History of severe allergy or intolerance to any contrast media, narcotics, sedatives, or atropine that cannot be corrected or premedicated; Bleeding diathesis, not correctable by usual forms of therapy; Severe peripheral vascular disease that would preclude catheterization.
  3. Evidence of potential delivery of greater than 16.5 mCi (30 Gy absorbed dose) of radiation to the lungs in a single treatment
  4. Clinical evidence of pulmonary insufficiency
  5. Evidence of any detectable Technetium-99 Macroaggregated Albumin (Tc-99m MAA) flow to the stomach or duodenum, after application of established angiographic techniques to stop or mitigate such flow.
  6. Complete occlusion of the main portal vein.
  7. Significant extrahepatic disease representing an imminent life-threatening outcome
  8. Active uncontrolled infection.
  9. Significant underlying medical or psychiatric illness.
  10. Co-morbid disease of condition that would preclude safe delivery of TheraSphere treatment or, in the judgment of the physician, place the patient at undue risk
  11. Pregnancy
  12. Tumor type demonstrated on imaging to be infiltrative, tumor volume > 70% of the target liver volume, or tumor nodules too numerous to count, or tumor volume > 50% combined with an albumin < 3 g/dL, or complete occlusion of the main portal vein.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01176604

Contact: Armeen Mahvash, MD 713-563-7340

United States, Texas
University of Texas MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
BTG International Inc.
Principal Investigator: Armeen Mahvash, MD M.D. Anderson Cancer Center
  More Information

Additional Information:
Responsible Party: M.D. Anderson Cancer Center Identifier: NCT01176604     History of Changes
Other Study ID Numbers: 2008-0770
NCI-2010-01956 ( Registry Identifier: NCI CTRP )
Study First Received: August 4, 2010
Last Updated: May 30, 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No

Keywords provided by M.D. Anderson Cancer Center:
Hepatocellular carcinoma (HCC) of the liver
Hepatocellular cancer
Hepatocellular carcinoma
Liver cancer
Humanitarian Device Exemption
Liver Diseases

Additional relevant MeSH terms:
Carcinoma, Hepatocellular
Liver Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases processed this record on August 16, 2017